Suggested remit: To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating enthesitis-related arthritis or juvenile psoriatic arthritis.
This topic is currently suspended whilst conversations between the company, NICE & NHS England are ongoing. A further update will be available in due course.
 
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 3738

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
01 March 2023 Suspended. This topic is currently suspended whilst conversations between the company, NICE & NHS England are ongoing. A further update will be available in due course.
31 July 2020 - 28 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual